J Cancer 2016; 7(3):283-288. doi:10.7150/jca.13295
Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer
1. Department of Radiation Oncology;
2. Department of Surgery;
3. Department of Medical Oncology; Beth Israel Deaconess Medical Center and Harvard Medical School, Boston MA.
Objectives: After adjuvant or definitive radiation for pancreas cancer, there are limited conventional treatment options for recurrent pancreas cancer. We explored the role of (Stereotactic Body Radiotherapy) SBRT for reirradiation of recurrent pancreas Cancer.
Methods: This is a retrospective study of patients reirradiated with SBRT for recurrent pancreas cancer. All patients were deemed unresectable and treated with systemic therapy. Fiducial gold markers were used. CT simulation was performed with oral and IV contrast and patients were treated with respiratory motion tracking in the CyberknifeTM system.
Results: 30 patients (17 men and 13 women) with a median age of 67 years were included in the study. The median target volume was 41.29cc. The median prescription dose was 25Gy (24-36Gy) in a median of 5 fractions prescribed to a mean 78% isodose line. The median overall survival was 14 months. The 1 and 2 year local control was 78%. The worst toxicity included 3/30(10%) Grade III acute toxicity for pain, bleeding and vomiting. There was 2/30 (7%) Grade III long-term bowel obstructions.
Conclusions: SBRT can be a useful and tolerable option for patients with recurrent pancreas cancer after prior radiation.
Keywords: Pancreatic Cancer, SBRT (Stereotactic Body Radiotherapy), Reirradiation
Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, Miksad R, Mancias JD, Mahadevan A. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer 2016; 7(3):283-288. doi:10.7150/jca.13295. Available from http://www.jcancer.org/v07p0283.htm